Skip to main content
27 June, 2022

Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich

Hyris presented its Hyris System™ and the new T Cells test in Munich last week, at Analytica 2022, the world largest laboratory technology fair.

At booth A3.115, Hyris team met new potential partners, clients and investors.

It was also a good chance for updating some market context and look at competitors products and releases.

Hyris System™ proved to be of interest for many players, with its disruptive approach to democratic genetics. Moreover, the newly launched innovative approach for T cells response measurement to SARS-CoV-2 has been appreciated by many practitioners.

The participation to Analytica 2022 confirmed Hyris committment to confront with market needs and dynamics, as well to offer customers and partners disruptive solutions, leveraging Hyris signature technology.

  • Hyris signs a distribution agreement with GrowBIGogh

  • Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

  • Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

  • Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

  • Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

  • Hyris' new onboarding programs support researchers and developers to launch testing kits.

  • Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

  • Hyris and Singlabs signed a distributorship agreement for Singapore

  • Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

  • Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine